

Supplementary Table 1. Relation between baseline characteristics and changes in BMD over the 10 year study period*

	Women				Men			
	Femoral Neck		Lumbar Spine		Femoral Neck		Lumbar Spine	
	Change/year	95% CI	Change/year	95% CI	Change/year	95% CI	Change/year	95% CI
Age	0.01	0.00; 0.03	0.02	0.01; 0.03	0.00	-0.02; 0.03	0.00	-0.03; 0.03
Post-menopausal	0.03	0.00; 0.06	0.04	0.01; 0.07	NA		NA	
BMI	0.00	-0.01; 0.02	0.00	-0.02; 0.01	-0.01	-0.03; 0.01	0.00	-0.03; 0.02
Smoking (ever)	-0.02	-0.06; 0.01	0.00	-0.03; 0.03	-0.01	-0.06; 0.04	-0.01	-0.08; 0.05
Symptom duration	0.01	0.00; 0.03	0.00	-0.01; 0.02	0.00	-0.02; 0.02	0.00	-0.03; 0.02
Positive RF	0.01	-0.02; 0.04	0.02	-0.01; 0.04	-0.04	-0.08; 0.00	-0.04	-0.09; 0.01
Positive anti-CCP	0.01	-0.03; 0.04	0.01	-0.02; 0.04	-0.03	-0.07; 0.01	-0.07	-0.12; -0.01
DAS28	-0.01	-0.03; 0.00	0.00	-0.02; 0.01	0.00	-0.02; 0.01	-0.02	-0.04; 0.00
HAQ	-0.01	-0.02; 0.01	0.01	-0.01; 0.02	0.00	-0.02; 0.02	0.01	-0.01; 0.04
ESR	-0.01	-0.02; 0.01	0.01	-0.01; 0.02	-0.01	-0.02; 0.01	-0.01	-0.03; 0.02
CRP>median	-0.01	-0.04; 0.02	0.01	-0.02; 0.04	-0.01	-0.05; 0.02	-0.03	-0.07; 0.02
VAS pain	-0.01	-0.03; 0.00	0.00	-0.02; 0.01	0.00	-0.02; 0.01	-0.01	-0.04; 0.01
VAS global	-0.01	-0.02; 0.01	0.00	-0.02; 0.01	-0.01	-0.03; 0.01	-0.02	-0.04; 0.00
Erosions	0.00	-0.04; 0.04	0.05	0.01; 0.09	-0.02	-0.06; 0.02	-0.01	-0.05; 0.06
Corticosteroids	-0.03	-0.06; 0.00	-0.01	-0.04; 0.02	-0.01	-0.05; 0.02	0.02	-0.03; 0.06
Calcium & D-vitamin	-0.01	-0.04; 0.03	0.00	-0.03; 0.03	-0.03	-0.07; 0.01	0.03	-0.02; 0.08
Bisphosphonates	0.00	-0.09; 0.09	0.05	-0.03; 0.14	NA		NA	
HRT	-0.01	-0.05; 0.03	-0.04	-0.07; 0.00	NA		NA	

* Mixed linear effect models; differences in change per year (Z-scores), per standard deviation or positive vs negative.

BMI: Body Mass Index. RF: Rheumatoid Factor. anti-CCP: anti-cyclic citrullinated protein. DAS28: Disease Activity Score-28. HAQ: Health Assessment Questionnaire. ESR: Erythrocyte Sedimentation Rate. CRP: C-reactive Protein. VAS: Visual Analogue Scale. CI: Confidence Interval. NA: not applicable.

There were no men with treatment with bisphosphonates (or HRT) at baseline. Bold text indicates significant associations.